Group II metabotropic glutamate receptors and schizophrenia

Cellular and Molecular Life Sciences : CMLS
José L MorenoJavier González-Maeso

Abstract

Schizophrenia is one of the most common mental illnesses, with hereditary and environmental factors important for its etiology. All antipsychotics have in common a high affinity for monoaminergic receptors. Whereas hallucinations and delusions usually respond to typical (haloperidol-like) and atypical (clozapine-like) monoaminergic antipsychotics, their efficacy in improving negative symptoms and cognitive deficits remains inadequate. In addition, devastating side effects are a common characteristic of monoaminergic antipsychotics. Recent biochemical, preclinical and clinical findings support group II metabotropic glutamate receptors (mGluR2 and mGluR3) as a new approach to treat schizophrenia. This paper reviews the status of general knowledge of mGluR2 and mGluR3 in the psychopharmacology, genetics and neuropathology of schizophrenia.

References

Aug 7, 2012·Nature Neuroscience·Mitsumasa KuritaJavier González-Maeso
Aug 13, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Louisa LyonDavid M Bannerman
Sep 27, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David M DietzEric J Nestler
Nov 17, 2010·Pharmacological Reviews·Nicola J Smith, Graeme Milligan
Jan 18, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Terrell HollowayJavier González-Maeso
Jun 4, 2014·Proceedings of the National Academy of Sciences of the United States of America·Natalia V MalkovaPaul H Patterson
Jul 8, 2015·Trends in Neurosciences·Amr EllaithyDiomedes E Logothetis
Dec 30, 2014·Acta neurologica Belgica·Stefanie DedeurwaerdereThomas Steckler
Feb 25, 2014·Biochemical and Biophysical Research Communications·Saranya KittanakomIgor Stagljar
Mar 4, 2015·ACS Chemical Neuroscience·Terrell Holloway, Javier González-Maeso
May 9, 2012·Neuropharmacology·Daniela DurandMercedes Lasaga
Mar 22, 2014·The International Journal of Neuropsychopharmacology·Maurizio S RigaPau Celada
Jun 1, 2016·Frontiers in Pharmacology·Carolina MuguruzaLuis F Callado
Feb 14, 2017·PLoS Computational Biology·Miguel FribourgVladimir Brezina
May 19, 2011·Clinical Neuropharmacology·Francisco López-Muñoz, Cecilio Álamo
Aug 9, 2017·Translational Psychiatry·S M SainiC A Bousman
Mar 17, 2017·Molecular Systems Biology·Kate SokolinaIgor Stagljar
Dec 21, 2012·Expert Review of Neurotherapeutics·Mitsumasa KuritaJavier González-Maeso
Jul 25, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mario de la Fuente RevengaJavier González-Maeso
Oct 13, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Lehao WuYan Zhang

Citations

Jan 1, 1997·Annual Review of Pharmacology and Toxicology·P J Conn, J P Pin
Sep 10, 1998·Nature Genetics·J L BlouinA E Pulver
Jul 3, 1999·Trends in Pharmacological Sciences·G J KilpatrickR M Eglen
Jan 29, 2000·Biological Psychiatry·S M Richardson-BurnsJ H Meador-Woodruff
May 17, 2000·American Journal of Medical Genetics·B P Riley, P McGuffin
Oct 12, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J C Gewirtz, Gerard J Marek
Aug 8, 2001·The Journal of Biological Chemistry·L GamaG E Breitwieser
Feb 13, 2002·American Journal of Medical Genetics·Sylvia Bort MartíMarkus Nöthen
Feb 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Daisuke TsuchiyaKosuke Morikawa
Jul 2, 2002·The American Journal of Psychiatry·Mary CannonRobin M Murray
Aug 22, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sergi FerréFrancisco Ciruela
Dec 5, 2002·Neurochemical Research·Elysia M HollamsPeter J Leedman
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Mar 15, 2003·Journal of Molecular Modeling·Anirban BhaduriRamanathan Sowdhamini
Jun 5, 2003·Pharmacology & Therapeutics·Jean-Philippe PinLaurent Prézeau
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mark A Geyer, Bart Ellenbroek
Dec 10, 2003·Archives of General Psychiatry·P SullivanMichael C Neale
Jan 8, 2004·EMBO Reports·Sonia Terrillon, Michel Bouvier
Mar 17, 2004·Current Opinion in Pharmacology·Gerard J Marek
Jul 6, 2004·Nature Structural & Molecular Biology·Julie KniazeffJean-Philippe Pin
Jul 21, 2004·Molecular Psychiatry·Paul J Harrison, D R Weinberger
Aug 18, 2004·Proceedings of the National Academy of Sciences of the United States of America·Michael F EganDaniel R Weinberger
Sep 2, 2004·Molecular Psychiatry·Carol A Tamminga, H H Holcomb
Sep 29, 2004·Biochemical Pharmacology·Jean-Philippe PinPhilippe Rondard
May 17, 2005·BMC Psychiatry·Nadine NortonMichael J Owen

Related Concepts

Metabotropic glutamate receptors type 3
Antipsychotic Effect
Assay OF Haloperidol
Schizophrenia
Clozapine
Receptors, Metabotropic Glutamate
GRM3 gene
Etiology
Haloperidol
Antipsychotic Agents

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Francesco MatriscianoAlessandro Guidotti
Pediatric Research
Stuart C Sealfon, Javier González-Maeso
Trends in Neurosciences
Javier González-Maeso, Stuart C Sealfon
© 2020 Meta ULC. All rights reserved